A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen; Pfizer

Criteria

Inclusion Criteria:

• Subjects must have a current diagnosis of age related sensorineural hearing loss in the range of 30-60 dB, averaged over 2 and 4 kHz in at least one ear.

• Subjects must have symmetric hearing loss

• Subjects who can read, speak and comprehend English.

Exclusion Criteria:

• Subjects who have a history of sudden hearing loss and history or diagnosis of rapidly progressive idiopathic hearing loss

• Subjects who have hearing disorders other than age related sensorineural hearing loss

• Subjects with moderate or greater tinnitus

• Pregnant females; breastfeeding females; females of childbearing potential